Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Dec 01, 2005 (Vol. 25, No. 21)

All Species Foundation

  • Species Toolkint
  • Too much blah, blah, blah
My analysis of this site took a sort of roller coaster approach. First, the topic was a high. With mass extinction of the planet currently underway, cataloging species while they are still with us is a very important project. As I started scrolling through the options at the site, I quickly discovered that ALL Species Foundation has lots of links that are mostly informational about the effort itself. They unfortunately provide little actual info about the species. Ouch! That was a definite low. Then, I clicked on the option entitled "Tools", which also contained a lot of blah, blah, blah. Fortunately, a single link within Tools led me to the associated Species Toolkit search engine, which is the only gem to be had here. There is information on 873,979 species and 1,124,819 names. One however, has to sort through a lot of commercially unrelated material to find the goodies. Not the best of schemes, unfortunately.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »